Have a personal or library account? Click to login

Hypoglycemic activity of Phaseolus vulgaris (L.) aqueous extract in type 1 diabetic rats

Open Access
|Dec 2019

References

  1. 1. IDF Diabetes Atlas 7th Edition 2015. Available: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html
  2. 2. Blair M. Diabetes Mellitus Review. Urol Nurs. 2016;36(1):27-36.10.7257/1053-816X.2016.36.1.27
  3. 3. Brealey D, Singer M. Hyperglycemia in critical illness: a review. J Diabetes Sci Technol. 2009;3(6):1250-60.10.1177/193229680900300604278702420144378
  4. 4. Dias DA, Urban S, Roessner U. A Historical Overview of Natural Products in Drug Discovery. Metabolites. 2012;2(2):303-36.10.3390/metabo2020303390120624957513
  5. 5. Chang CL, Chen YC, Chen HM, et al. Natural cures for type 1 diabetes: a review of phytochemicals, biological actions, and clinical potential. Curr Med Chem. 2013;20(7):899-907.10.2174/0929867311320070006
  6. 6. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277-94.10.2337/diacare.26.4.127712663610
  7. 7. Covington MB. Traditional Chinese medicine in the treatment of diabetes. Diabetes Spectr. 2001;14:154-9.10.2337/diaspect.14.3.154
  8. 8. Ota A, Ulrih NP. An overview of herbal products and secondary metabolites used for management of type two diabetes. Front Pharmacol. 2017;8:436.10.3389/fphar.2017.00436549930828729836
  9. 9. Pandey VN, Rajagopalan SS, Chowdhary DP. An effective Ayurvedic hypoglycemic formulation. J Res Ayurveda Siddha. 1995;1-14.
  10. 10. Oubre AY, Carlson TJ, King SR, et al. From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia. 1997;40:614-17.10.1007/s0012500507249165233
  11. 11. Karimi A, Majlesi M, Rafieian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol. 2015;4(1):27-30.
  12. 12. Bharti SK, Krishnan S, Kumar A, et al. Antidiabetic phyto-constituents and their mode of action on metabolic pathways. Ther Adv Endocrinol Metab. 2018;9(3):81-100.10.1177/2042018818755019581385929492244
  13. 13. Chávez-Mendoza C, Sánchez E. Bioactive compounds from Mexican varieties of the Common Bean (Phaseolus vulgaris): implications for health. Molecules. 2017;22(8),1360.10.3390/molecules22081360
  14. 14. Reynoso-Camacho R., Ramos-Gomez M., Loarca-Pina G. Bioactive components in common beans (Phaseolus vulgaris L.). Research Signpost. 2006;37/661(2):217-36.
  15. 15. Helmstädter A. Beans and diabetes: Phaseolus vulgaris preparations as antihyperglycemic agents. J Med Food. 2010;13(2):251-4.10.1089/jmf.2009.000220132042
  16. 16. Zafar M, Naqvi S. Effects of STZ-induced diabetes on the relative weights of kidney, liver and pancreas in Albino rats: A comparative study. Int J Morphol. 2010;28(1):135-42.10.4067/S0717-95022010000100019
  17. 17. Sabu MC, Subburaju T. Effect of Cassia auriculata Linn. on serum glucose level, glucose utilization by isolated rat hemidiaphragm. J Ethnopharmacol. 2002;80:203-6.10.1016/S0378-8741(02)00026-0
  18. 18. Stasevych M, Zvarych V, Lunin V, et al. Novel anthraquinone-based derivatives as potent inhibitors for receptor tyrosine kinases. Indian J Pharm Sci. 2015;77(5):634-7.10.4103/0250-474X.169062
  19. 19. Carai MAM, Fantini N, Loi B, et al. Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism. Diabetes Metab Syndr Obes. 2009;2:145-53.10.2147/DMSO.S4236
  20. 20. Roman-Ramos R, Flores-Saenz JL, Partida-Hernandez G, et al. Experimental study of the hypoglycemic effect of some edible plants. Arch Invest Med (Mex). 1991;22:87-93.
  21. 21. Roman-Ramos R, Flores-Saenz JL, Alarcon-Aguilar F. Antihyperglycemic effect of some edible plants. J Ethnopharmacol. 1995;48:25-32.10.1016/0378-8741(95)01279-M
  22. 22. Pari L, Venkateswaran S. Effect of an aqueous extract of Phaseolus vulgaris on plasma insulin and hepatic key enzymes of glucose metabolism in experimental diabetes. Pharmazie. 2003;58:916-9.
  23. 23. Almuaigela MF, Seifb MA, Albualia HW, Alharbia O, Alhawasha A. Hypoglycemic and hypolipidemic effects of aqueous extract of phaseolus vulgaris pods in streptozotocin-diabetic rats. Biomedicine & Pharmacotherapy. 2017; 94:742-6.10.1016/j.biopha.2017.07.13528800543
  24. 24. Pari L, Venkateswaran S. Protective role of Phaseolus vulgaris on changes in the fatty acid composition in experimental diabetes. J Med Food. 2004;7(2):204-9.10.1089/109662004122412015298769
  25. 25. Neef H, Declercq P, Laekeman G. Hypoglycemic activity of selected European plants. Phytother Res. 1995;9:45-8.10.1002/ptr.2650090111
  26. 26. Cerovic A, Miletic I, Konic.-Ristic A, et al. The dry plant extract of common bean seed (Phaseoli vulgari pericarpium) does not have an affect on postprandial glycemia in healthy human subject. Bosn J Basic Med Sci. 2006;6(3):28-33.10.17305/bjbms.2006.3140719365716995844
  27. 27. Kyznetsova MY, Lavrovska DO, Zhyvolozhnyi AY, et al. Effect of aqueous extract from Phaseolus vulgaris pods on cytokine profile of streptozotocin-induced diabetic rats. RJPBCS. 2015;6(1):1511-20.
  28. 28. Kyznietsova MY, Halenova TI, Savchuk OM, et al. Carbohydrate metabolism in type 1 diabetic rats under the conditions of the kidney bean pods aqueous extract application. Fiziol Zh. 2015;61(6):96-103.10.15407/fz61.06.09627025050
  29. 29. Kyznetsova M, Makieieva O, Lavrovska D, et al. Aqueous extract from Phaseolus vulgaris pods on lipid peroxidation and antioxidant enzymes activity in the liver and kidney of diabetic rats. J Appl Pharm Sci. 2015; 5(5):001-6.10.7324/JAPS.2015.50501
  30. 30. Oseguera Toledo ME, Gonzalez de Mejia E, Sivaguru M, et al. Common bean (Phaseolus vulgaris L.) protein-derived peptides increased insulin secretion, inhibited lipid accumulation, increased glucose uptake and reduced the phosphatase and tensin homologue activation in vitro. J Funct Foods. 2016; 27:160-77.10.1016/j.jff.2016.09.001
  31. 31. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216-26.10.1007/s00125-007-0886-718087688
  32. 32. Lim M, Park L, Shin G, Hong H, Kang I, Park Y. Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Ann NY Acad Sci. 2008;1150:311-5.10.1196/annals.1447.01119120318
  33. 33. Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10:24.10.1186/1475-2891-10-24307177821414227
  34. 34. Baintner K, Kiss P, Pfüller U, et al. Effect of orally and intraperitoneally administered plant lectins on food consumption of rats. Acta Physiol Hung. 2003; 90(2):97-107.10.1556/APhysiol.90.2003.2.212903908
DOI: https://doi.org/10.2478/cipms-2019-0036 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 210 - 218
Submitted on: Feb 19, 2019
Accepted on: Apr 24, 2019
Published on: Dec 31, 2019
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2019 Tetiana Halenova, Natalia Raksha, Olha Kravchenko, Tetiana Vovk, Alona Yurchenko, Igor Vareniuk, Olexii Savchuk, Ludmila Ostapchenko, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.